PSNL earnings call summary

Prepared Highlights

• Clinical test volume: Q4 2025 delivered 6,183 tests, up 41% sequentially vs. Q3 2025 and 329% YoY (from 1,441 in Q4 2024) (CEO). Full-year 2025: >16,000 tests, growing 394% over 2024 (CEO).
• Total revenue: Q4 2025: $17.3M, +3% YoY ($16.8M) (CFO). Full-year 2025: $69.6M (CFO). Revenue decline from Natera ($19.5M) and Moderna melanoma trial conclusion ($10M) offset by 239% growth in biopharma MRD revenue (CFO).
• Clinical revenue: Q4 2025: $0.9M; full-year 2025: $2.0M (vs. $0.2M and $0.8M in 2024) (CFO). Includes initial breast cancer surveillance revenue covered by Medicare in Q4 (CFO).
• Biopharma revenue: Q4 2025: $10.9M (vs. $12.2M Q4 2024); full-year 2025: $49M (vs. $51M in 2024) (CFO). Decline due to Moderna volume decrease (CFO).
• Gross margin: Q4 2025: 11%; full-year 2025: 22.7% (CFO). Unreimbursed costs diluted margins by ~1,900 bps in Q4 (CFO).
• Operating expenses: Q4 2025: $27.2M (vs. $22.7M Q4 2024); full-year 2025: $103.8M (vs. $95.1M 2024) (CFO). Increase driven by commercial and R&D investments (CFO).
• Net loss: Q4 2025: $23.8M (vs. $16.4M Q4 2024); full-year 2025: $81.3M (same as 2024) (CFO).
• Cash & investments: $240M at Q4 2025 end, no debt (CFO). Full-year 2025 cash usage ~$74M (CFO).
• RPO/backlog: Not stated.

Official Guidance (2026)

• Total revenue: $78M–$80M (CFO).
• Clinical revenue: $10M–$11M (from breast and lung cancer surveillance tests covered by Medicare) (CFO).
• Pharma test & services revenue: $55M–$56M; MRD revenue from these customers: $20M–$21M (CFO).
• Population sequencing + enterprise: ~$13M (CFO).
• Gross margin: 15%–20%, with Q1 potentially the lowest point (CFO).
• Net loss: ~$105M (CFO).
• Cash usage: ~$100M (CFO).
• Clinical test volume: 43,000–45,000 tests (CEO).

Mgmt Quotes

• "2025 was the year we validated our winning MRD strategy. 2026 is the year we expect to scale." (CEO)
• "We are no longer dependent on a single legacy contract. We are building a diversified and sustainable high-growth engine." (CFO)
• "The margin dynamic is driven by the strong growth in volume of NeXT Personal tests ahead of reimbursement revenue." (CFO)
• "We expect our strategic revenue to grow from approximately $14 million in 2025 to a range of $30 million to $32 million in 2026, which would be roughly 121% growth." (CEO)
• "We are setting our initial 2026 annual volume guidance at 43,000 to 45,000 tests, which would be about 170% growth year-over-year." (CEO)

Prepared Metrics

Q&A Batch (1-5 of 7)

Q1 — Subhalaxmi Nambi

• Topic: 报销进展对销售重点、商业化合作及生物制药业务的影响
• Key points:
  • 2026年收入指引为4300万至4500万美元，代表激进投资与谨慎现金管理之间的平衡。
  • 未来可能的报销进展（如IO）或收钱方式改善，可进一步增加投资。
  • 生物制药业务是重要增长驱动，过去2-3年投入大量时间建立并发展该业务。
• Mgmt stance: 中性偏积极；报销为业务提供合法性，增强与医生沟通的说服力，但管理层强调会根据实际情况逐步调整投资节奏。

Q2 — Vidyun Bais

• Topic: 生物制药合同情况、MRD业务重要性及2026年临床测试量构成
• Key points:
  • 生物制药板块正趋于稳定，未见合同取消或推迟，但大公司尚未大规模回归转化用途；反映在指引中。
  • MRD业务2025年收入同比增长近240%，且2024年基数已很强，2026年预计继续增长。
  • 2026年测试量指引为43,000–45,000例：乳腺癌约占20%，肺癌15%-20%，IO 20%-25%，结直肠癌约20%，其他约20%。
  • 目前仅乳腺癌和肺癌获报销，低于一半的测试有付款（Medicare约占总量的50%的一半，即约25%有报销）。
• Mgmt stance: 中性偏积极；MRD业务增长强劲，客户为大型公司且通过头对头数据竞争获胜，但生物制药领域回暖仍需时间。

Q3 — Thomas Flaten

• Topic: 现金状况与盈亏平衡目标、实时变异追踪器（opt-in模块）采纳情况及医生深化策略
• Key points:
  • 年末现金2.4亿美元，2026年预计使用1亿美元，按当前消耗速度可维持约2.5年；明确未承诺现金达到盈亏平衡。
  • 实时变异追踪器为opt-in模块，早期访问计划正在筹备中，医生对此表示兴奋。
  • 目标为在现有900位处方医生中深化用量，而非单纯扩张数量，长期客户订单量更大。
• Mgmt stance: 中性偏积极；现金充裕足以支撑未来几年投资和市场份额争夺，但仍未设定盈亏平衡时间点。

Q4 — Unknown Analyst

• Topic: 2026年临床测试量季度增长节奏、竞争格局（新进入者与整合）
• Key points:
  • 2025年Q4临床测试量为6,183例，可作为线性推算起点；Q2和Q4为旺季，Q1和Q3因假期、天气等因素为淡季。
  • MRD市场规模预计超200亿-300亿美元；当前只有2家真正肿瘤来源产品，PNL在超敏领域领先。
  • 公司有30多项在研研究，并与Tempus建立独家商业合作，具备快速执行力。
• Mgmt stance: 积极；公司已证明执行能力，并凭借超敏产品、数据领先优势和合作网络，在竞争中获得并保持份额。

Q5 — William Bonello

• Topic: 临床量指引上调背后的策略转变、毛利率路径、现金消耗及与Tempus的合作尺度
• Key points:
  • 2024年因无报销且现金较少而克制销售；如今获得乳腺癌和肺癌报销、现金增至2.4亿美元，因此决定加速投资抢占市场份额。
  • 2026年预计现金消耗7400万至1亿美元，毛利率短期因部分无报销测试而承压，目标先至低60%，最终达70%。
  • 指引未假设任何新增报销（如IO）；若未来实现更多报销，存在上行空间。
  • Tempus获得更多自由度以加深现有账户合作，但管理层表示整体投资节奏仍保持平衡（2026年新增10名销售代表，总数翻倍）。
• Mgmt stance: 积极；管理层认为市场窗口期有限，必须加速投资以巩固超敏MRD领域领先地位，尽管短期会牺牲现金和毛利率。

Q&A Batch (6-7 of 7)

Q6 — Joseph Conway

• Topic: CRC and neoadjuvant breast reimbursement timeline, evidence generation strategy, and gross margin drivers
• Key points:
  • No exact timeline for CRC and neoadjuvant breast reimbursement submissions; dependent on publication acceptance (not in guidance).
  • Evidence strategy continues with top KOLs for baseline data; strong data debuted in neoadjuvant breast and CRC at conferences last year.
  • Inbound interest from KOLs for clinical utility studies using the assay to show impact on outcomes, important for guidelines.
  • Lab automation and workflow streamlining ongoing; capacity added stepwise to avoid weighing on margins; biopharma fee-for-service and potential IO reimbursement (not in guide) could help move margins to upper end or beyond.
• Mgmt stance: Neutral – management is driving hard for submissions but acknowledges variability; operational improvements are incremental and not fully completed.

Q7 — Thomas Stevens

• Topic: Adjuvant reimbursement expectations, neoadjuvant opportunity in pharma trials, and market sizing
• Key points:
  • Adjuvant breast and lung reimbursement is a focus, pursued similarly to other successful indications.
  • Neoadjuvant use in biopharma is high interest; drugs moving earlier in treatment; ultrasensitive assay shown to perform well vs. pCR in triple-negative breast and HER2-positive (data presented last year).
  • No market size estimate provided for neoadjuvant clinical market; patient journey for MRD starts with neoadjuvant but is a small fraction of total testing (surveillance over many years is larger).
• Mgmt stance: Neutral – management confirms focus on adjuvant but provides no timeline or sizing; neoadjuvant opportunity acknowledged as early but limited relative to surveillance.